Next Article in Journal
Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
Next Article in Special Issue
Recurrent Superior Vena Cava Syndrome in a Patient with Sarcoidosis and Pancreatic Adenocarcinoma: A Case Report and Literature Review
Previous Article in Journal / Special Issue
Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study
Review

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

1
Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi Hospital, University of Bologna, 40128 Bologna, Italy
2
Center of Applied Biomedical Research, S. Orsola-Malpighi University Hospital, 40128 Bologna, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Medicines 2020, 7(9), 54; https://doi.org/10.3390/medicines7090054
Received: 26 July 2020 / Revised: 25 August 2020 / Accepted: 29 August 2020 / Published: 31 August 2020
Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. BRCA1/2 mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spectrum of DDR gene alterations is reported in 28.9–63.5% of newly diagnosed BTC patients. The open question is whether alterations in genes that are well established to have a role in DDR could be considered as emerging predictive biomarkers of response to platinum compounds and PARPi. Currently, data regarding PARPi in BTC patients harboring BRCA and DDR mutations are sparse and anecdotal; nevertheless, a variety of clinical trials are testing PARPi as monotherapy or in combination with other anticancer agents. In this review, we provide a comprehensive overview regarding the genetic landscape of DDR pathway deficiency, state of the art and future therapeutic implications of PARPi in BTC, looking at combination strategies with immune-checkpoint inhibitors and other anticancer agents in order to improve survival and quality of life in BTC patients. View Full-Text
Keywords: biliary tract cancer; cholangiocarcinoma; PARP; BRCA; olaparib; rucaparib; liver cancer biliary tract cancer; cholangiocarcinoma; PARP; BRCA; olaparib; rucaparib; liver cancer
Show Figures

Figure 1

MDPI and ACS Style

Ricci, A.D.; Rizzo, A.; Bonucci, C.; Tober, N.; Palloni, A.; Mollica, V.; Maggio, I.; Deserti, M.; Tavolari, S.; Brandi, G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines 2020, 7, 54. https://doi.org/10.3390/medicines7090054

AMA Style

Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines. 2020; 7(9):54. https://doi.org/10.3390/medicines7090054

Chicago/Turabian Style

Ricci, Angela D., Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, and Giovanni Brandi. 2020. "PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?" Medicines 7, no. 9: 54. https://doi.org/10.3390/medicines7090054

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop